The epidemiology of intravenous vancomycin usage in a university hospital. A 10-year study.
about
Increasing resistance to vancomycin and other glycopeptides in Staphylococcus aureusReducing vancomycin use utilizing a computer guideline: results of a randomized controlled trialEmergence of vancomycin resistant Staphylococcus aureus (VRSA) from a tertiary care hospital from northern part of India.Analysis of vancomycin use and associated risk factors in a university teaching hospital: a prospective cohort study.Vancomycin-induced thrombocytopenia in a 60-year-old man: a case report.In vivo activity of ceftobiprole in murine skin infections due to Staphylococcus aureus and Pseudomonas aeruginosa.Serum cystatin C predicts vancomycin trough levels better than serum creatinine in hospitalized patients: a cohort study.Excessive use of vancomycin: a successful intervention strategy at an academic medical center.Practical guidelines for vancomycin usage, with prospective drug-utilization evaluation.Vancomycin use in pediatric hematology-oncology patients.Reduced susceptibility of Staphylococcus aureus to vancomycin and platelet microbicidal protein correlates with defective autolysis and loss of accessory gene regulator (agr) functionVancomycin resistance in staphylococci.Molecular epidemiology of vancomycin-resistant Enterococcus faecium in a large urban hospital over a 5-year period.Vancomycin-resistant enterococci.Identification of aerobically and anaerobically induced genes in Enterococcus faecalis by random arbitrarily primed PCRMethicillin and Vancomycin Resistant S. aureus in Hospitalized Patients.Evidence of inappropriate use of vancomycin in a university affiliated hospital in Brazil.Beta-lactams versus glycopeptides in treatment of subcutaneous abscesses infected with Staphylococcus aureus.Vancomycin and home health care.Evaluating vancomycin use at a pediatric hospital: new approaches and insights.Microbiological features of vancomycin in the 21st century: minimum inhibitory concentration creep, bactericidal/static activity, and applied breakpoints to predict clinical outcomes or detect resistant strains.Effects of Pharmacist Intervention on the Utilization of Vancomycin in a Teaching Hospital.Vancomycin-resistant enterococci outside the health-care setting: prevalence, sources, and public health implicationsVancomycin resistance: are there better glycopeptides coming?Multidrug-Resistant Bacteria in the Community: Trends and Lessons Learned.Inappropriate vancomycin prescribing based on criteria from the Centers for Disease Control and Prevention.Pediatric vancomycin dosing: Trends over time and the impact of therapeutic drug monitoring.Impact of vancomycin therapeutic drug monitoring on patient care.Mississippi mud in the 1990s: risks and outcomes of vancomycin-associated toxicity in general oncology practice.The serum vancomycin assay: A test of historic interest.Evaluation of Tigecycline Activity Against Methicillin-Resistante Staphylococcus aureus Isolated from Biological Samples.Use of glycopeptides at a French teaching hospital.Clinical analysis of combination therapy for febrile neutropenic patients in childhood cancer.Vancomycin in Oregon: who's using it and why.Evaluation of vancomycin therapy in the adult ICUs of a teaching hospital in southern Iran.
P2860
Q28362193-0F1D411C-3FA3-4B4E-80EF-275DC9D31C89Q30453838-23C1A9BF-7260-4497-80CD-B6039928B588Q33261667-EC7F9EB9-6739-42B0-804B-415F2C619AA5Q33293228-0F1120C4-13A1-4513-8776-1481840F4FD2Q33386648-E5FA3EB8-290B-4F1E-9953-AD7ECC5B1022Q33559139-A78DF587-4378-4037-A1C1-EBA7132DCDECQ33821959-CD74A00B-28C2-4149-A37A-239F0F6D4B8CQ33828665-5EF6A824-55CA-4530-9BD7-9DCC4ADAC8B3Q33828670-52468CE1-02DD-40F1-B52E-56CA49675194Q33828674-D6A99987-21A8-4ABE-B3F1-25DCFC449C2AQ33883752-5CF7459C-1BA5-4D3E-82EB-52E005C1DC35Q33906522-FCD34F8E-E9CA-4356-A940-B2B1A1D0A2A7Q33964133-53F5A707-F09E-412D-BE68-A469D07282DBQ33975592-2900941F-13FD-4924-A07B-0A3E0661B74AQ33984589-72399204-AE10-4333-8384-2F06E6D3AA34Q34142160-B93331C1-8C51-4F4D-AC2F-035D50D0E4E8Q35741955-079FE52B-DE4B-416C-B590-A1E6DF9D5EA2Q35820407-BDB5D8C1-5762-487D-B070-F024A86F937CQ36006700-11179F31-6AFA-47B5-A2B7-138947D3DEF9Q36031273-91E1C8FA-F3CD-409C-8FB8-A593EFE282E4Q36328966-87D335A5-4CED-4CB3-A300-8676A29D3603Q36358439-4843432F-E735-48EF-953D-E78614587CC0Q37064230-39F4ECD6-D220-41BF-8E3D-60398946CFF8Q37340562-C3C63826-ACB0-40DD-9DBC-7617C069730AQ37648626-A0C58634-9859-406C-A77F-F76FED0995CAQ40950966-A1FBAA78-4E7F-41D9-8596-E928847B0AA6Q41723791-09613805-6F9D-4C14-99F5-A435013C2CEBQ42278351-252EB05F-F380-4F64-90E2-2A48B255B1AAQ42537120-A23DBAA0-2528-47C3-B7EE-5171ABF629A8Q42591040-F1A38AB6-7859-4AEA-A12B-C0F519D29836Q42781919-608472E1-F5AA-4E38-A812-30FDC7BCD62AQ44596494-F72C4CC9-7608-497A-9A77-94E7C6EA14A3Q51287696-9AA2B56C-D50C-4C7E-8C4A-D25C65EA9398Q54080782-60ECF648-AFB3-4D9A-AA36-E527715E9AE4Q54232841-C241DF85-17B9-4CE6-A6DE-98C2F0F612C9
P2860
The epidemiology of intravenous vancomycin usage in a university hospital. A 10-year study.
description
1993 nî lūn-bûn
@nan
1993年の論文
@ja
1993年学术文章
@wuu
1993年学术文章
@zh
1993年学术文章
@zh-cn
1993年学术文章
@zh-hans
1993年学术文章
@zh-my
1993年学术文章
@zh-sg
1993年學術文章
@yue
1993年學術文章
@zh-hant
name
The epidemiology of intravenou ...... ity hospital. A 10-year study.
@en
The epidemiology of intravenou ...... ity hospital. A 10-year study.
@nl
type
label
The epidemiology of intravenou ...... ity hospital. A 10-year study.
@en
The epidemiology of intravenou ...... ity hospital. A 10-year study.
@nl
prefLabel
The epidemiology of intravenou ...... ity hospital. A 10-year study.
@en
The epidemiology of intravenou ...... ity hospital. A 10-year study.
@nl
P2093
P1476
The epidemiology of intravenou ...... ity hospital. A 10-year study.
@en
P2093
P304
P356
10.1001/JAMA.1993.03500050076029
P407
P577
1993-02-01T00:00:00Z